Trials / Completed
CompletedNCT03700320
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 744 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standard of Care (SOC) Migraine Preventive Medication | Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine. |
| DRUG | Atogepant | Atogepant tablets taken orally, once daily for 52 weeks. |
Timeline
- Start date
- 2018-10-08
- Primary completion
- 2020-05-21
- Completion
- 2020-05-21
- First posted
- 2018-10-09
- Last updated
- 2021-06-15
- Results posted
- 2021-06-15
Locations
112 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03700320. Inclusion in this directory is not an endorsement.